MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Clinical Manifestations
Clinical Manifestations
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical Manifestations
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Clinical Manifestations
Clinical Manifestations

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Clinical Manifestations
Journal Article

Clinical Manifestations

2024
Request Book From Autostore and Choose the Collection Method
Overview
Neuropsychiatric symptoms (NPS) in the Alzheimer's Disease (AD) clinical spectrum are common, yet the pathological underpinnings are unclear. Prior research has been inconsistent, attributed in part to concomitant co-pathologies. Additionally, prior modeling approaches have disregarded the distributional properties of right-skewed NPS data and utilized predominantly racially homogenous cohorts. Thus, we examined the relationship between NPS and markers of vascular injury and neurodegeneration using generalized linear models (GLM) in a diverse community-based sample. Of additional interest was whether these relationships differed by cognitive status or race. We evaluated cross-sectional relationships of brain white matter hyperintensity volume (WMHv) and plasma neurofilament light chain (pNfL) to NPS (NPI-Q total severity scores) in 588 Wake Forest ADRC Clinical Core study participants. Analyses included participants with consensus diagnoses of cognitively unimpaired (CU; N = 348) and mild cognitive impairment (MCI; N = 240). WMHv and pNfL were log-transformed prior to model entry. GLMs included age, sex, education, race, and cognitive status as covariates and pathologies as predictor variables. Secondary models included aforementioned covariates and pathology by (a) cognitive status and (b) race interaction terms to investigate how these associations differed. WMHv was not significantly associated with NPS (N = 561; β = 0.203; p = 0.053); further, we did not observe an interaction between cognitive status and WMHv (N = 561; β = -0.055; p = 0.800). However, a significant race by WMHv interaction on NPI-Q was demonstrated (N = 561; β = -0.414; p = 0.016). In White participants, elevated WMHv was significantly related to elevated NPS (N = 434; β = 0.325; p = 0.006); whereas in Black/African American participants elevated WMHv was significantly related to lower NPS (N = 119; β = -0.239; p = 0.049). pNfL was not significantly associated with NPS (N = 506; β = 0.149; p = 0.576). A significant pNfL by cognitive status interaction on NPI-Q was found (N = 506; β = -1.055; p = 0.029; Figure 2), where elevated pNfL was related to elevated NPS in MCI participants (N = 198; β = 1.656; p = 0.004) but not CU participants (N = 308; β = -0.316; p = 0.260). However, we did not observe an interaction between race and pNfL (N = 506; β = 0.185; p = 0.678). Consistent with previous work we demonstrate associations of pNfL and WMHv with NPS. Future analyses with this cohort will examine additional biomarkers, including amyloid-beta and tau measured in CSF, plasma, and PET.